((自动化翻译由路透提供，请见免责声明 ))
10月8日 - ** Sage Therapeutics 股价盘前下跌13%，报5.86美元
** 由于未能达到中期研究的主要目标，SAGE计划停止进一步开发治疗 阿尔茨海默病的实验药物dalzanemdor
** Dalzanemdor 的试验目的是治疗阿尔茨海默病引起的轻度认知障碍或轻度痴呆症
** 在这项有174人参加的研究中，根据一种广泛使用的认知能力量表来衡量，该药物在患者与安慰剂之间没有显示出统计学上的显著差异。
** 公司称，该药物的耐受性总体良好，研究中未发现新的安全信号
** SAGE 还在亨廷顿氏症相关认知障碍患者中测试这种药物，计划在今年晚些时候报告中期数据。
** 截至上次收盘，SAGE年累计跌幅约为69%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.